SynthesisInflammopharmacology2026
Anti-inflammatory activity of Silver Nanoparticles (AgNPs): An Updated Systematic review from in vivo, and in vitro studies.
Synthesis in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is a fundamental immune response implicated in the pathogenesis of chronic diseases, tissue injury, cancer, and aging. Conventional anti-inflammatory therapies, though effective, are usually limited by systemic toxicity and long-term safety concerns. Silver nanoparticles have emerged as promising nanotherapeutic agents owing to their multi-functional biological properties. This review thoroughly summarizes recent developments (2015-2025) in the anti-inflammatory potential of AgNPs, with focus on their physicochemical characteristics, synthesis strategies, and underlying molecular mechanisms. Evidence from in-vivo and in-vitro studies presented that AgNPs regulate key inflammatory pathways by inhibiting NF-κB and MAPK signaling, supressing pro-inflammatory cytokines, reducing oxidative stress, and regulating macrophage polarization. Green synthesized AgNPs specifically showed improved therapeutic efficacy and biocompatibility. Additionally, application of AgNPs in arthritis, inflammatory bowel condition, and wound healing are discussed alongside toxicological challenges, and safety considerations. Altogether, AgNPs represent a versatile platform for upcoming anti-inflammatory therapies, supporting further translational and clinical investigation.
Indexed as
Identifiers
41746596What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.